{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:03:19Z","timestamp":1762542199816},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T00:00:00Z","timestamp":1378944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s00228-013-1583-8","type":"journal-article","created":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T08:50:27Z","timestamp":1378889427000},"page":"13-21","source":"Crossref","is-referenced-by-count":11,"title":["Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes"],"prefix":"10.1007","volume":"70","author":[{"given":"Yaguo","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enci","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changming","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,12]]},"reference":[{"key":"1583_CR1","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"N Galie","year":"2009","unstructured":"Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30:2493\u20132537","journal-title":"Eur Heart J"},{"key":"1583_CR2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","volume":"142","author":"RL Benza","year":"2012","unstructured":"Benza RL, Miller DP, Barst RJ et al (2012) An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 142:448\u2013456","journal-title":"Chest"},{"key":"1583_CR3","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","volume":"351","author":"M Humbert","year":"2004","unstructured":"Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Eng J Med 351:1425\u20131436","journal-title":"N Eng J Med"},{"key":"1583_CR4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","volume":"327","author":"BW Christman","year":"1992","unstructured":"Christman BW, McPherson CD, Newman JH et al (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Eng J Med 327:70\u201375","journal-title":"N Eng J Med"},{"key":"1583_CR5","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0140-6736(84)91452-1","volume":"1","author":"T Higenbottam","year":"1984","unstructured":"Higenbottam T, Wheeldon D, Wells F et al (1984) Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1:1046\u20131047","journal-title":"Lancet"},{"key":"1583_CR6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","volume":"31","author":"M Gomberg-Maitland","year":"2008","unstructured":"Gomberg-Maitland M, Olschewski H (2008) Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 31:891\u2013901","journal-title":"Eur Respir J"},{"key":"1583_CR7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","volume":"127","author":"ZC Jing","year":"2013","unstructured":"Jing ZC, Parikh K, Pulido T et al (2013) Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: A randomized, controlled trial. Circulation 127:624\u2013633","journal-title":"Circulation"},{"key":"1583_CR8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","volume":"142","author":"VF Tapson","year":"2012","unstructured":"Tapson VF, Torres F, Kermeen F et al (2012) Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): A randomized controlled trial. Chest 142:1383\u20131390","journal-title":"Chest"},{"key":"1583_CR9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","volume":"126","author":"NB Gabler","year":"2012","unstructured":"Gabler NB, French B, Strom BL et al (2012) Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 126:349\u2013356","journal-title":"Circulation"},{"key":"1583_CR10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2012.01.083","volume":"60","author":"G Savarese","year":"2012","unstructured":"Savarese G, Paolillo S, Costanzo P et al (2012) Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 60:1192\u20131201","journal-title":"J Am Coll Cardiol"},{"key":"1583_CR11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA et al (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Eng J Med 334:296\u2013301","journal-title":"N Eng J Med"},{"key":"1583_CR12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/eurheartj\/ehp022","volume":"30","author":"N Galie","year":"2009","unstructured":"Galie N, Manes A, Negro L et al (2009) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 30:394\u2013403","journal-title":"Eur Heart J"},{"key":"1583_CR13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ahj.2007.02.037","volume":"153","author":"A Macchia","year":"2007","unstructured":"Macchia A, Marchioli R, Marfisi R et al (2007) A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 153:1037\u20131047","journal-title":"Am Heart J"},{"key":"1583_CR14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1465-9921-11-12","volume":"11","author":"CJ Ryerson","year":"2010","unstructured":"Ryerson CJ, Nayar S, Swiston JR et al (2010) Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. Respir Res 11:12","journal-title":"Respir Res"},{"key":"1583_CR15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1185\/03007995.2013.802682","volume":"29","author":"T Li","year":"2013","unstructured":"Li T, Chen Y, Zang W et al (2013) Prostacyclin and its analogues in pulmonary artery hypertension: a meta-analysis. Curr Med Res Opin 29:889\u2013999","journal-title":"Curr Med Res Opin"},{"key":"1583_CR16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","volume":"29","author":"J Hiremath","year":"2010","unstructured":"Hiremath J, Thanikachalam S, Parikh K et al (2010) Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung transpl 29:137\u2013149","journal-title":"J Heart Lung transpl"},{"key":"1583_CR17","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","volume":"55","author":"VV McLaughlin","year":"2010","unstructured":"McLaughlin VV, Benza RL, Rubin LJ et al (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 55:1915\u20131922","journal-title":"J Am Coll Cardiol"},{"key":"1583_CR18","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","volume":"174","author":"VV McLaughlin","year":"2006","unstructured":"McLaughlin VV, Oudiz RJ, Frost A et al (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174:1257\u20131263","journal-title":"Am J Respir Crit Care Med"},{"key":"1583_CR19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","volume":"28","author":"MM Hoeper","year":"2006","unstructured":"Hoeper MM, Leuchte H, Halank M et al (2006) Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 28:691\u2013694","journal-title":"Eur Respir J"},{"key":"1583_CR20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","volume":"41","author":"VV McLaughlin","year":"2003","unstructured":"McLaughlin VV, Gaine SP, Barst RJ et al (2003) Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41:293\u2013299","journal-title":"J Cardiovasc Pharmacol"},{"key":"1583_CR21","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","volume":"41","author":"RJ Barst","year":"2003","unstructured":"Barst RJ, McGoon M, McLaughlin V et al (2003) Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119\u20132125","journal-title":"J Am Coll Cardiol"},{"key":"1583_CR22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","volume":"165","author":"G Simonneau","year":"2002","unstructured":"Simonneau G, Barst RJ, Galie N et al (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Resp Crit Care Med 165:800\u2013804","journal-title":"Am J Resp Crit Care Med"},{"key":"1583_CR23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","volume":"347","author":"H Olschewski","year":"2002","unstructured":"Olschewski H, Simonneau G, Galie N et al (2002) Inhaled iloprost for severe pulmonary hypertension. N Eng J Med 347:322\u2013329","journal-title":"N Eng J Med"},{"key":"1583_CR24","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","volume":"39","author":"N Galie","year":"2002","unstructured":"Galie N, Humbert M, Vachiery JL et al (2002) Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496\u20131502","journal-title":"J Am Coll Cardiol"},{"key":"1583_CR25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","volume":"132","author":"DB Badesch","year":"2000","unstructured":"Badesch DB, Tapson VF, McGoon MD et al (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425\u2013434","journal-title":"Ann Intern Med"},{"key":"1583_CR26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","volume":"112","author":"LJ Rubin","year":"1990","unstructured":"Rubin LJ, Mendoza J, Hood M et al (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112:485\u2013491","journal-title":"Ann Intern Med"},{"key":"1583_CR27","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","volume":"54","author":"G Simonneau","year":"2009","unstructured":"Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43\u201354","journal-title":"J Am Coll Cardiol"},{"key":"1583_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"1583_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.epirev.a036298","volume":"9","author":"S Greenland","year":"1987","unstructured":"Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9:1\u201330","journal-title":"Epidemiol Rev"},{"key":"1583_CR30","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/eurheartj\/ehn333","volume":"29","author":"RP Whitlock","year":"2008","unstructured":"Whitlock RP, Chan S, Devereaux PJ et al (2008) Clinical benefit of steroid use in patients undergoing cardiopulmonary bypass: a meta-analysis of randomized trials. Eur Heart J 29:2592\u20132600","journal-title":"Eur Heart J"},{"key":"1583_CR31","doi-asserted-by":"crossref","unstructured":"Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","DOI":"10.1136\/bmj.315.7109.629"},{"key":"1583_CR32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1378\/chest.06-2118","volume":"132","author":"M Rubenfire","year":"2007","unstructured":"Rubenfire M, McLaughlin VV, Allen RP et al (2007) Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest 132:757\u2013763","journal-title":"Chest"},{"key":"1583_CR33","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1253\/circj.CJ-09-0971","volume":"74","author":"B He","year":"2010","unstructured":"He B, Zhang F, Li X et al (2010) Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 74:1458\u20131464","journal-title":"Circ J"},{"key":"1583_CR34","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","volume":"28","author":"RJ Barst","year":"2006","unstructured":"Barst RJ, Galie N, Naeije R et al (2006) Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28:1195\u20131203","journal-title":"Eur Respir J"},{"key":"1583_CR35","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","volume":"40","author":"O Sitbon","year":"2002","unstructured":"Sitbon O, Humbert M, Nunes H et al (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40:780\u2013788","journal-title":"J Am Coll Cardiol"},{"key":"1583_CR36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000334431","volume":"120","author":"Y Bai","year":"2011","unstructured":"Bai Y, Sun L, Hu S et al (2011) Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology 120:157\u2013165","journal-title":"Cardiology"},{"issue":"Suppl 1","key":"1583_CR37","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/01.mcp.0000370206.61003.7e","volume":"16","author":"N Galie","year":"2010","unstructured":"Galie N, Simonneau G, Barst RJ et al (2010) Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med 16[Suppl 1]:S11\u201319","journal-title":"Curr Opin Pulm Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1583-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-013-1583-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-013-1583-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T18:52:54Z","timestamp":1563907974000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-013-1583-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1007\/s00228-013-1583-8","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,12]]}}}